# Chronic Hepatitis D Infection FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-hepatitis-d-infection

> 6 upcoming FDA catalysts in chronic Hepatitis D Infection: brelovitug (MIRM) on Jun to Sep 2027 (topline data readout); ABI-6250 (ASMB) on June 2027 (primary completion); ABI-6250 (ASMB) on Jun to Sep 2027 (topline data readout); brelovitug (MIRM) on June 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| August 2026 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | delayed | "NCT07298330 (A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07298330)) |
| Q4 2026 | [Brelovitug topline data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "Brelovitug is currently being evaluated in the global AZURE clinical program with topline results from the AZURE-1 and AZURE-4 registration-enabling clinical trials expected in the third and fourth quarter of 2026, respectively, and top-line results from the AZURE-2 and AZURE-3 registration-enabling clinical trials expected by the first half of 2028." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1759425/000175942526000045/mirm-20260630.htm)) |
| Jun to Sep 2027 | [Brelovitug topline data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT07200908 (A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07200908)) |
| June 2027 | [ABI-6250 primary completion](https://sec-api.dev/pdufa/abi-6250) | ASMB | Chronic Hepatitis D Infection | scheduled | "NCT07762027 (A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Assembly Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07762027)) |
| Jun to Sep 2027 | [ABI-6250 topline data readout](https://sec-api.dev/pdufa/abi-6250) | ASMB | Chronic Hepatitis D Infection | scheduled | "NCT07762027 (A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Assembly Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07762027)) |
| June 2027 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT07200908 (A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07200908)) |
| May 2029 | [Brelovitug primary completion](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT06907290 (A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06907290)) |
| May to Aug 2029 | [Brelovitug topline data readout](https://sec-api.dev/pdufa/brelovitug) | MIRM | Chronic Hepatitis D Infection | scheduled | "NCT06907290 (A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Mirum Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06907290)) |

## Drugs

- [Brelovitug](https://sec-api.dev/pdufa/brelovitug) (MIRM)
- [ABI-6250](https://sec-api.dev/pdufa/abi-6250) (ASMB)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-hepatitis-d-infection.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Hepatitis D Infection FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-hepatitis-d-infection

```bibtex
@misc{secapidev_indications_chronic_hepatitis_d_infection_20261116,
  title        = {Chronic Hepatitis D Infection FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-hepatitis-d-infection}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_hepatitis_d_infection_20261116","title":"Chronic Hepatitis D Infection FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-hepatitis-d-infection","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
